Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial

BACKGROUND: Intravenous zoledronate 5 mg annually reduces fracture risk, and 5 mg every 2 years prevents bone loss, but the optimal dosing regimens for these indications are uncertain. METHODS: We conducted a 3-year open-label extension of a 2-year randomized, placebo-controlled, double-blind study....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CMAJ
Hauptverfasser: Grey, Andrew, Bolland, Mark J., Horne, Anne, Mihov, Borislav, Gamble, Greg, Reid, Ian R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Joule Inc. 2017
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595552/
https://ncbi.nlm.nih.gov/pubmed/28893875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/cmaj.161207
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge